Vitamin D deficiency is highly prevalent due to lifestyle and environmental factors which limit sunlight induced vitamin D production in the skin. This "pandemic" of vitamin D deficiency is of concern because low levels of -hydroxyvitamin D ( [OH]D) have been associated with cardiovascular, musculoskeletal, infectious, autoimmune and malignant diseases. Epidemiological studies have largely but not consistently shown that vitamin D deficiency is a risk factor for strokes. This is supported by associations of low (OH)D levels with cerebrovascular risk factors, in particular with arterial hypertension. Vitamin D has also been shown to exert neuroprotective, neuromuscular and osteoprotective effects which may reduce cognitive and functional impairments in poststroke patients. Hence, the current literature favours the notion that vitamin D supplementation is a promising approach for the prevention and treatment of strokes but accurate data from interventional studies are missing. Randomized controlled trials are therefore urgently needed to evaluate whether vitamin D supplementation reduces the incidence of strokes and improves the outcome of poststroke patients. We do, however, believe that currently published data on the multiple health benefits of vitamin D and the easy safe and inexpensive way by which it can be supplemented already argue for the prevention and treatment of vitamin D deficiency in order to reduce stroke associated morbidity and mortality.
Introduction
A poor vitamin D status is currently considered as a public health problem because it affects almost every second person worldwide and has been associated with various adverse health consequences [, ] . Accumulating evidence suggests that vitamin D deficiency is associated with cardiovascular [-], renal [] , musculoskeletal [, , ] , malignant [-] , infectious [] and autoimmune diseases [] . Previous studies have also indicated that a poor vitamin D status may be associated with both an increased risk of strokes and adverse health outcomes of poststroke patients [-] . This is of particular importance because stroke is the third most common cause of death and one of the leading causes of disability [-] . Most strokes are of ischemic origin whereas approximately - % of strokes are the result of intracerebral hemorrhage [, ] . Given its high incidence, the prevention and treatment of strokes is an im-portant goal to reduce the related burden of morbidity, mortality and health-care costs.
In this brief review we summarize the current knowledge on the relationship of vitamin D status and stroke starting with a brief summary on vitamin D metabolism. Then, we outline associations of vitamin D and risk factors for strokes. Furthermore, we present evidence from epidemiological studies on the association of a poor vitamin D status with the prevalence and incidence of strokes. Finally, we discuss possible health benefits of vitamin D for the treatment of stroke patients in order to reduce stroke related disabilities and co-morbidities.
Literature search strategy
For this review we performed a systematic literature search in Pubmed for relevant English language publications published until January . We entered the following search terms: "vitamin D" and "stroke" as well as "vitamin D" and "cerebrovascular". We also used the search terms "hydroxyvitamin D", ",-dihydroxyvitamin D" or "calcitriol" instead of vitamin D. Personal collections of articles on this topic as well as references from selected articles were also used to expand the search. Some articles were not cited due to space limitations.
Vitamin D metabolism
In general, sunlight (ultraviolet [UV]-B) induced vitamin D production in the skin is the main source for vitamin D whereas vitamin D intake by nutrition plays usually only a minor role [] . Lifestyle and environmental factors which limit sunlight exposure of the skin are therefore mainly responsible for the current "pandemic" of vitamin D deficiency [, ] . It should also be mentioned that food fortification with vitamin D is performed in several countries but is often not effective in preventing vitamin D deficiency [, ] . On the other hand, vitamin D supplementation during the first  to  years of life is generally recommended and effective in preventing rickets [] . Vitamin D itself is biologically not very active and has to be hydroxylated to exert its genomic and non-genomic effects as a steroid hormone. As a first step, vitamin D is hydroxylated to -hydroxyvitamin D ([OH]D) in the liver. Then,  (OH)D is further hydroxylated to ,(OH)D which has the highest affinity for the vitamin D receptor (VDR) but circulates in much lower concentrations than (OH) D. The VDR is almost ubiquitously expressed and regulates approximately three percent of the human genome [] . Circulating levels of ,(OH)D are mainly determined by α-hydroxylation of (OH)D to ,(OH)D in the kidney, which is stimulated by e.g. low calcium and high parathyroid hormone (PTH). Interestingly, it has been shown that α hydroxylation occurs on a local level in many different cells and organs [] . Tissue levels of ,(OH)D seem to be mainly a result of this local α-hydroxylation of (OH)D. Blood levels of kidney derived ,(OH)D are, however, not a good estimate of locally produced ,(OH)D in extra-renal tissues because of differentially regulated α-hydroxylase activities [] . Considering that local extrarenal synthesis of ,(OH)D is significantly determined by circulating (OH)D levels it is widely accepted that serum levels of (OH)D are the best estimate of  whole-body vitamin D status [, ] . (OH)D levels are therefore used to classify the vitamin D status into vitamin D deficiency (< ng/ml), vitamin D insufficiency ( to  ng/ml) and vitamin D sufficiency (≥ ng/ml) (multiply by . to convert ng/ ml to nmol/l) [] . Vitamin D intoxication occurs when (OH)D levels are higher than  ng/ml and adverse effects of vitamin D are almost exclusively driven by hypercalcemia [,] . -hydroxylation is a main step in the degradation of (OH)D and ,(OH)D but the biological relevance of the resulting vitamin D metabolites is still largely unclear. Low (OH)D levels can be easily treated by vitamin D supplementation. It can be expected that supplementation of , IU vitamin D per day raises (OH)D levels by approximately  ng/ml [] . Individual variations in the response to vitamin D supplementation should, however, be considered and therefore it appears reasonable to consider remeasurements of (OH)D after about  months of treatment. In particular obese individuals who are at increased stroke risk require much higher vitamin D doses compared to normal weight individuals to achieve a sufficient (OH)D status [] . Of note, vitamin D can be supplemented in daily, weekly or monthly doses which result in similar increases in (OH)D levels [] . Sun exposure can also increase vitamin D levels up to a maximum increase which is equivalent to daily vitamin D intakes of up to , IU, but possible side effects of increased sun exposure must be considered [] . Active vitamin D treatment with ,(OH)D is commonly performed in patients with endstage renal disease [] . In contrast to natural vitamin D, supplementation of ,(OH)D has a relatively narrow therapeutic window with the risk of hypercalcemia if ,(OH)D is overdosed [] . Hence, various analogues of vitamin D have been developed which exert less calcemic side effects and may offer some additional benefits compared to ,(OH)D (e.g. enhanced antiproliferative or immunoregulative activity) [, ] .
Vitamin D deficiency and risk factors for strokes
Previous studies have shown that low (OH)D levels are associated with an increased risk for cardiovascular events [, -] . This association seems to be at least in part mediated by associations of vitamin D deficiency with risk factors for ischemic and hemorrhagic strokes [, ] . In this chapter we will outline the possible pathways by which vitamin D deficiency might be related to increased stroke risk.
Arterial Hypertension and Metabolic Syndrome
Arterial hypertension, one of the most significant risk factors for strokes, has been associated with vitamin D deficiency [] . Towards this, various clinical studies have largely but not consistently shown an association of vitamin D deficiency as well as low UV-B radiation with increased blood pressure [] . Antihypertensive effects of vitamin D seem to be mainly mediated by suppression of the reninangiotensin-aldosterone system, prevention of hyperparathyroidism, renoprotective and anti-inflammatory effects as well as vasculoprotective properties [] . Randomized controlled trials in this field are rare but a recent meta-analysis showed that natural vitamin D therapy reduces systolic blood pressure by -. mm Hg (% CI -. to -.) and diastolic blood pressure by -. mm Hg (% CI -. to .) [] . Beyond hyper-tension, vitamin D deficiency has also been linked to all other components of the metabolic syndrome, which is a risk factor for strokes itself. In detail, it has been documented that vitamin D deficiency is associated with increased risk of type  diabetes mellitus [] . Large interventional studies are still missing but results from small randomized controlled trials suggest that vitamin D supplementation improves insulin sensitivity and reduces insulin resistance [-] . Proposed anti-diabetic properties of vitamin D include stimulation of insulin secretion, upregulation of the insulin-receptor and anti-inflammatory effects [] . Interstingly, type  diabetes may also be associated with vitamin D deficiency which is supported by an inverse association of both UV-B radiation and vitamin D intake during childhood with the incidence of type  diabetes [, ] . Pathophysiological mechanisms remain speculative but there is evidence that vitamin D increases regulatory T cells which protect against autoimmune diseases [, ] . Large epidemiological studies revealed an increased prevalence of dyslipidemia in patients with low (OH)D levels [, , ] . A recent randomized controlled trial has shown that vitamin D supplementation significantly increases HDL-cholesterol and lowers triglycerides but a slight increase in LDL-cholesterol levels was also observed [] . Given that statin therapy is associated with reduced incidence of strokes it should be underlined that a recent study showed a better lipid response to atorvastatin in patients with high compared to low (OH) D levels [] . In addition, previous study results suggest that statin treatment might increase (OH)D levels but data on this topic are inconsistent [-] . In observational studies vitamin D deficiency has also been linked to both increased body mass index as well as increased waist to hip ratio [, ] . Data from interventional trials are inconclusive but largely failed to show significant reductions in body weight or body fat after vitamin D supplementation [, , ] . Hence, it appears that low (OH)D levels in obese persons are rather the consequence of vitamin D storage in adipose tissue or reduced sunlight exposure than the cause of obesity.
Atherosclerosis
Atherosclerosis, in particular of the carotid arteries, contributes to cerebrovascular ischemia. Data on the association of carotid intima-media thickness and (OH)D levels are, however, inconsistent [-] . Some studies showed no association [, ] whereas others reported that low (OH)D levels are independently associated with carotid intima-media thickness [, ] . From a pathophysiological point of view, vitamin D deficiency may contribute to atherosclerosis by its proposed associations with classic cardiovascular risk factors but may additionally exert direct proatherosclerotic effects. In detail, vitamin D deficiency may contribute to endothelial dysfunction, pro-atherosclerotic changes of vascular smooth muscle cells (VSMC) and to increased macrophage to foam cell formation [-] . It should, however, be noted that supraphysiological doses of ,(OH)D or its analogues can also be deleterious with promotion of vascular calcification [] .
Prothrombotic States
Thrombotic and thrombembolic events are the most common cause of ischemic strokes. Experimental animal studies suggest that vitamin D may prevent thrombosis by upregulation of thrombomodulin and by suppression of plasminogen activator inhibitor type- (PAI-), thrombospondulin , and the procoagulaant tissue factor [] . Significant reductions of venous and arterial thrombosis in a placebo controlled trial with high doses of ,(OH)D in prostate cancer patients are in favour of antithrombotic effects of the vitamin D endocrine system [] . This is in line with a recent study on an inverse association of (OH)D levels with increased thrombotic activity [] . In the same study, vitamin D supplementation, did, however, not affect parameters of the thrombogram [] . Apart from this, it should be considered that myocardial diseases which predispose to cardio-embolic events and which are considered risk factors for strokes have also been associated with vitamin D deficiency [-] .
Secondary Hyperparathyroidism
Vitamin D is a key regulator of calcium homeostasis. It is frequently observed that low calcium levels caused by vitamin D deficiency stimulate PTH secretion resulting in secondary hyperparathyroidism. Elevated PTH levels in secondary hyperparathyroidism maintain serum calcium levels within the normal range and stimulate renal conversion of (OH)D to ,(OH)D but may also exert some deleterious effects. Of note, initial definitions of vitamin D deficiency were based on (OH)D cut-off levels at which PTH levels start to rise. Previous studied showed that elevated PTH was associated with a history of strokes and PTH was significantly higher in female stroke patients compared to age matched controls [, ] . PTH has also been shown to exert pro-atherosclerotic effects and is associated with arterial hypertension [] . A recent communitybased study showed that PTH levels predicted overall cardiovascular mortality and similar results have been found in patients referred to coronary angiography [, ] . Hence, it can be hypothesized that PTH elevations in patients with vitamin D deficiency may also contribute to an increased risk of cerebrovascular events.
Inflammation
Inflammation is considered a risk factor for strokes [] . Various studies suggest that vitamin D may exert anti-inflammatory effects [, , , , ]. Data on this topic are, however, not fully consistent but Zittermann and Schleithoff et al. demonstrated in randomized placebo controlled trials that vitamin D supplementation decreased the inflammatory parameter tumor necrosis factor-α (TNF-α) and increased the anti-inflammatory cytokine interleukin- [, ] . On the other hand it should also be stressed that vitamin D deficiency may increase the risk of infections which may trigger cerebrovascular events [] . An overview of the associations of vitamin D deficiency with risk factors for stroke is shown in Fig. () .


Epidemiology of vitamin D deficiency and stroke risk
A large body of evidence from epidemiological studies indicates that vitamin D deficiency is associated with increased risk of strokes. Interestingly, numbers of studies examined whether there are seasonal and regional differences in the incidence of strokes [-] . Results were inconsistent but the picture of many of these studies is that stroke incidence appears to increase in winter and at lower altitudes [-] . In general, winter season and lower altitude are associated with low UV-B radiation and subsequently lower (OH)D levels. We are aware that there are many plausible explanations for these latter findings but in our opinion the seasonal and geographic differences in stroke incidences fit well to the hypothesis that low (OH)D levels are a risk factor for cerebrovascular events [-] . In line with this, Poole et al. showed that patients within  days of a first-ever stroke presented with significantly lower  (OH)D levels when compared to healthy elderly subjects [] . Marniemi et al. examined  elderly subjects who were followed-up for up to  years [] . Seventy strokes occurred during the observational period but there was no significant difference in (OH)D levels between cases (.±. ng/ml) and controls (.±. ng/ml) [] . However, compared to the lowest tertile in , (OH)D levels, the risk of stroke was significantly reduced in the highest tertile with a relative risk of . (% CI .-.) [] . Bolland et al. studied  health com-munity-dwelling women (mean age  years) who participated in a -years randomized placebo controlled trial with calcium supplementation [] . Hazard ratios (HR) (with % CI) for stroke in a crude model and a model adjusted for cardiovascular risk factors were . (.-.) and . (.-.), respectively, in women with seasonally adjusted (OH)D levels below  ng/ml compared to women with higher  (OH)D levels [] . The increased stroke risk was particularly pronounced in women allocated to calcium, which showed a HR for stroke in the vitamin D deficient group of . (.-.) in unadjusted analyses [] . After adjustments for possible confounders, however, all observed associations of low (OH)D levels and increased risk of stroke lost their significance [] . We addressed this issue in the LUdwigshafen RIsk and Cardiovascular Health (LURIC) Study, a prospective follow-up study among  patients referred for coronary angiography [] . During a median follow-up time of . years,  patients died due to fatal strokes. Risk of fatal stroke was significantly reduced per increase in month of blood sampling adjusted z values of both (OH)D and ,(OH)D. The HRs (with % CI) adjusted for cardiovascular risk factors were . (.-.) for (OH)D and . (.-.) for ,(OH)D, respectively [] . Kilkkinen et al. published data from the Mini-Finland Health Survey, a study among  men and women aged ≥  years who were free of cardiovascular disease at baseline [] . During a median follow-up time of . years,  cerebrovascular disease deaths were recorded. After adjustment for cardiovascular risk factors, the HR for cerebrovascular death was . (.-.) in the highest versus the lowest (OH)D quintile. More in depth analyses revealed that the adjusted HRs for hemorrhagic stroke and ischemic stroke were . (.-.) and . (.-.), respectively, in the highest versus the lowest (OH)D tertile [] . At the American Heart Association scientific sessions in , Bair et al. presented yet unpublished data from a prospective follow-up analysis among , persons aged at least  years and with no history of cardiovascular disease [] . After one year of follow-up persons with (OH)D levels below  ng/ml were at % higher risk to die due to stroke than individuals with (OH)D levels >  ng/ml [] . Randomized controlled trials are rare and were not adequately powered to detect differences in the incidence of strokes [-] . In the Women's Health Initiative (WHI), , postmenopausal women were randomly allocated to either  mg calcium plus  IU vitamin D per day or placebo [, ] . During a follow-up of  years  strokes were recorded and the HR in the treatment versus the placebo group was . (.-.) [] . In analyses of the WHI Study restricted to fatal cerebrovascular events (n=), the HR was . (.-.) in the treatment versus the placebo group. Subgroup analyses revealed a respective HR of . (.-.) in patients younger than  years and a HR of . (.-.) in older study participants [] . Interpretations of these above mentioned non-significant reductions in strokes in the calcium plus vitamin D group are difficult. Even the authors of the WHI Study acknowledged that main limitations such as the extremely low dose of  IU vitamin D daily and the poor adherence to study medication were significant drawbacks of their work which preclude any final conclusions on cardiovascular health benefits of vitamin D plus calcium supplementation [, ] . Another randomized controlled trial by Trivedi et al. among  elderly persons was performed with a four monthly supplementation of , IU vitamin D [] . There were only  fatal strokes after a follow-up of five years with no significant difference between the treatment and the placebo group ( versus  fatal strokes) [] . A limitation of most large vitamin D interventional trials is the lack of PTH measurements which are required to conclude whether the achieved  (OH)D levels were sufficient to treat or prevent potentially harmful PTH elevations. In general, randomized controlled trials did not consider individual variations in the response to vitamin D supplementation. This is an important point when considering that obese patients, which are at increased stroke risk, require doses up to , IU per day to replete their vitamin D status [] . Taken together, observational studies are largely in favour of the hypothesis that vitamin D may protect against strokes but only few interventional studies are available until now, and these have some methodological limitations. Hence, whether vitamin D protects against stroke remains to be proven in randomized controlled trials.
Role of vitamin D for the treatment of stroke patients
Poststroke patients may benefit from a sufficient vitamin D status because apart from its proposed effects in the prevention of (recurrent) strokes, vitamin D is suggested to reduce neurological, psychological and musculoskeletal diseases in these patients.
Neuroprotective and Neuromuscular Effects of Vitamin D
Cerebral ischemia was shown to stimulate expression of VDR and α-hydroxylase along with increased VDR activation, indicating a role of the vitamin D endocrine system in stroke patients [] . In a rat model of cerebral ischemia induced by ligation of the middle cerebral artery, pretreatment with ,(OH)D for  days was associated with a significant reduction in infarct size of the ischemic brain [] . In the same study Wang et al. is not yet clearly established [] . Furthermore, most of the data on (OH)D and cognitive function were derived from crosssectional studies which precludes conclusions regarding the directionality of the observed associations. Apart from this, Jorde et al. reported about amelioration of depressive symptoms in a randomized placebo controlled trial among  overweight and obese subjects [] . Further studies on vitamin D and depression are still needed but poststroke patients would significantly benefit from anti-depressive vitamin D effects [, ] . Finally, there is evidence that vitamin D exerts anticonvulsant effects which might be useful for prevention and treatment of poststroke epilepsy [, ] . One of the most important goals in the treatment of stroke patients is the functional recovery of paretic extremities and neuromuscular disorders [] . In a  years randomized placebo controlled trial among  elderly women with poststroke hemiplegia Sato et al. found significantly improved muscle strength in the vitamin D group, which received , IU daily [] . Furthermore, vitamin D intake was associated with a % (% CI -%) reduction in falls [] . This is an important finding when considering the markedly increased risk of falls in poststroke patients with subsequently higher risk of (hip) . In this randomized placebo controlled trial among  ambulatory patients with history of falls and (OH)D levels ≤  ng/ml there was a significant improvement in functional performance, reaction time and balance but no effect on muscle strength in the vitamin D group [] . Hence, there is accumulating evidence that a sufficient vitamin D status may be beneficial for neuromuscular function in stroke patients.
Osteoporosis and Fractures
Compared to a reference population, stroke patients are at a  to  times higher risk of fractures, in particular hip fractures which are associated with an increased mortality [] . Sato et al. studied  stroke patients who were followed up for  years for occurrences of fractures. Patients with (OH)D levels below  ng/ml were at significantly increased risk of hip fractures [] . Numerous further studies by the group of Sato et al. as well as of others have indicated that vitamin D deficiency is associated with accelerated bone resorption and reduced bone mineral density in stroke patients [-] . Importantly, a randomized trial with sunlight exposure among  stroke patients showed a significant increase in bone mineral density in the treatment group [] . It should be considered that the adverse effects of vitamin D deficiency on bone metabolism seem to be aggravated by immobilisation of paretic extremities. Immobilisation associated hypercalcemia, which is mainly a result of increased bone resorption, is not uncommon in these patients and may lead to severe suppression of renal ,(OH)D synthesis. Beyond low (OH)D levels, these suppressed ,(OH)D concentrations may also be very deleterious when considering previous studies which showed increased all-cause and cardiovascular mortality in patients with low ,(OH)D levels [, -]. The above mentioned evidence underlines that vitamin D therapy, which is routinely recommended for osteoporosis treatment, is a promising therapeutic approach to reduce the burden of osteoporosis in stroke patients. Vitamin D effects on neuromuscular function as well as on bone and mineral metabolism may act in concert to prevent poststroke fractures. Apart from this, various other suggested properties of vitamin D such as anti-infectious or anti-thrombotic properties might be beneficial for poststroke patients [, , , , , ]. An overview of the associations of vitamin D deficiency with stroke related comorbidities and complications is shown in Fig. () . 
Summary and discussion
We have presented evidence that vitamin D deficiency is associated with an increased risk of strokes. This notion is supported by accumulating studies showing that several risk factors for cerebrovascular events are associated with low (OH)D levels. In addition, findings from cross-sectional and longitudinal studies underlined that vitamin D deficiency is common in patients presenting with acute stroke and indicates an increased risk for future strokes. Reverse causality may, however, also be present and we can therefore not exclude that depressed (OH)D levels are simply the consequence of strokes as well as other adverse health consequences related to vitamin D deficiency (see Fig. () and Fig. () ). Hence, whether the association of vitamin D deficiency and strokes is of causal nature remains to be proven in further randomized controlled trials. Apart from this, it should be stressed that poststroke patients, who are usually less frequently exposed to sunlight, are at particularly increased risk of vitamin D deficiency. This is an important issue because vitamin D has been shown to exert neuroprotective, neuromuscular and osteoprotective effects which might minimize cognitive and functional impairments in poststroke patients. We also want to stress that vitamin D has been shown to exert multiple beneficial health effects (e.g. anti-carcinogenic effects) beyond its proposed role in the prevention and treatment of strokes. Hence, it could be hypothesized that a widely introduced vitamin D treatment might be beneficial for many diseases beyond strokes. This enthusiastic goal of public health strategies to fight against vitamin D deficiency is supported by a recent meta-analysis of randomized controlled trials, which showed a significant % reduction in total mortality in patients treated with vitamin D [] . We have to acknowledge that we cannot uncritically raise a general recommendation to supplement vitamin D in the prevention and treatment of strokes unless we have supportive findings from adequately designed randomized controlled trials. We do, however, believe, that the possible health benefits outweigh the respective risks and costs of approaches to achieve a sufficient vitamin D status in the prevention and treatment of strokes. In this context we want to draw the attention towards the facts that (i) vitamin D insufficiency affects almost every second person worldwide as well as most stroke patients and (ii) that vitamin D supplementation is easy, safe and cheap. Nevertheless, further randomized controlled trials are urgently needed to prove whether vitamin D supplementation reduces the incidence of strokes and improves the outcome of poststroke patients. 
